FY2023 · ended Dec 31, 2023 · Revenue $1.43M, -86.7% YoY · Filed Mar 28, 2025
Perspective Therapeutics, Inc. (CATX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$95.2 million. As of Jun 30, 2026 it held $236.9 million in cash and investments and $4.0 million in total debt.
Revenue
$1.43M
-86.7% vs prior year
Net income
$-103.12M
-30.1% vs prior year
Operating cash flow (TTM)
$-93.07M
-43.7% vs year-ago TTM
Free cash flow (TTM)
$-121.19M
-5.6% vs year-ago TTM
EPS
$-1.40
-13.8% vs prior year
Dividend per share
None
Shares outstanding
113.93M
+53.9% vs prior year
Net cash
$232.91M
as of Jun 30, 2026
Operating margin
-2855.0%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CATX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 728387
- Former names
- IsoRay, Inc. (until Feb 16, 2023); Isoray, Inc. (until Feb 16, 2023); CENTURY PARK PICTURES CORP (until Aug 3, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Jun 30, 2022 |
FY 2021 Jun 30, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $1.4M | $10.8M | $10.1M |
| Operating income | -$113.6M | -$90.9M | -$40.9M | -$6.4M | -$3.4M |
| Net income | -$103.1M | -$79.3M | -$46.5M | -$7.3M | -$3.4M |
| Diluted EPS | -$1.40 | -$1.23 | — | — | — |
| Operating cash flow | -$82.5M | -$18.3M | -$36.9M | -$7.7M | -$2.8M |
| Free cash flow | -$95.2M | -$72.7M | -$38.0M | -$8.0M | -$3.2M |
| Total assets | $267.0M | $341.1M | $97.9M | $64.4M | $70.4M |
| Total liabilities | $59.9M | $50.4M | $22.7M | $3.2M | $3.0M |
| Stockholders' equity | $207.0M | $290.7M | $75.2M | $61.3M | $67.4M |
| Cash and investments | $144.7M | $226.9M | $9.2M | $55.9M | $63.8M |
| Total debt | $3.3M | $4.1M | $2.6M | $524,000 | $776,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
All 1002 Perspective Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.